WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced today the milestone of the 100th robotic-assisted percutaneous coronary intervention (PCI) case performed using the Company’s second-generation CorPath GRX System. Since its commercial launch in January 2017, the CorPath GRX System has been used successfully in a variety of procedural settings and physicians have reported an increase in the number of procedures that can be performed robotically.
Sunil Rao, MD, Section Chief of Cardiology at the Durham VA Medical Center, stated, "The CorPath GRX System is an important advancement in the field of interventional cardiology and I am pleased to be a part of the initial launch of this enhanced technology. The addition of active guide management has allowed me to increase the number of interventional procedures I perform robotically, and as a result, I was able to complete several difficult cases entirely using the CorPath GRX System."
The CorPath GRX System offers improvements in procedural control, enhanced workflow and radiation protection for physicians, patients and staff. Since its commercial launch, the CorPath GRX System has been used successfully in a variety of PCI cases including complex multi-vessel disease, NSTEMI, left radial access, diffused and calcified lesions, FFR, ostial RCA and subtotal 99% occlusions.
"The completion of the first 100 cases using our CorPath GRX System represents a significant milestone for Corindus," said Mark Toland, President and CEO of Corindus. "The early feedback from our customers has been positive and we are excited to continue our U.S. commercial roll-out throughout the rest of this year."
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.
Forward Looking Statements
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.
Examples of such statements are that:
- the ability to perform complex procedures and strong emphasis on physician and staff education enable broad market implementation of CorPath robotic programs and
- the Company will continue its U.S. commercial roll-out of the CorPath GRX System throughout the rest of 2017.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.